Valentis (Pharmaceuticals) Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Valentis (Pharmaceuticals) General Information

Description

Developer of technologies for medicinal purpose. The company's technologies include multiple gene delivery and gene expression systems and PEGylation, which are designed to improve the safety, efficacy and dosing characteristics of genes, proteins, peptides, peptidomimetics, antibodies and viruses.

Contact Information

Formerly Known As
Megabios
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 533 Airport Boulevard
  • Suite 400
  • Burlingame, CA 94010
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Corporate Office
  • 533 Airport Boulevard
  • Suite 400
  • Burlingame, CA 94010
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Valentis (Pharmaceuticals) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 16-Jul-2007 Completed Generating Revenue
9. PIPE 02-Jun-2006 Completed Generating Revenue
8. PIPE 28-Jun-2005 Completed Generating Revenue
7. PIPE 20-Aug-2004 Completed Generating Revenue
6. PIPE 10-Jun-2004 Completed Generating Revenue
5. PIPE 30-Jan-2004 Completed Generating Revenue
4. PIPE 31-Dec-2003 Completed Generating Revenue
3. PIPE 18-Sep-2003 Completed Generating Revenue
2. PIPE 14-Apr-2000 $19.2M $19.2M Completed Generating Revenue
1. Early Stage VC 30-Sep-1996 Completed Generating Revenue
To view Valentis (Pharmaceuticals)’s complete valuation and funding history, request access »

Valentis (Pharmaceuticals) Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
BCM Ventures Venture Capital Minority
BIT (AXA Framlington Investment Managers) Mutual Fund Minority
BSI-AG Other Minority
Banca Investis Investment Bank Minority
Compania Financiera Lender/Debt Provider Minority
You’re viewing 5 of 11 investors. Get the full list »

Valentis (Pharmaceuticals) Acquisitions (1)

Valentis (Pharmaceuticals)’s most recent deal was a Reverse Merger with Vaneltix Pharma. The deal was made on 16-Jul-2007.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vaneltix Pharma 16-Jul-2007 Reverse Merger Drug Discovery
To view Valentis (Pharmaceuticals)’s complete acquisitions history, request access »

Valentis (Pharmaceuticals) FAQs

  • When was Valentis (Pharmaceuticals) founded?

    Valentis (Pharmaceuticals) was founded in 1992.

  • Where is Valentis (Pharmaceuticals) headquartered?

    Valentis (Pharmaceuticals) is headquartered in Burlingame, CA.

  • What industry is Valentis (Pharmaceuticals) in?

    Valentis (Pharmaceuticals)’s primary industry is Drug Discovery.

  • Is Valentis (Pharmaceuticals) a private or public company?

    Valentis (Pharmaceuticals) is a Private company.

  • What is Valentis (Pharmaceuticals)’s current revenue?

    The current revenue for Valentis (Pharmaceuticals) is .

  • How much funding has Valentis (Pharmaceuticals) raised over time?

    Valentis (Pharmaceuticals) has raised $67.9M.

  • Who are Valentis (Pharmaceuticals)’s investors?

    BCM Ventures, BIT (AXA Framlington Investment Managers), BSI-AG, Banca Investis, and Compania Financiera are 5 of 11 investors who have invested in Valentis (Pharmaceuticals).

  • When was Valentis (Pharmaceuticals) acquired?

    Valentis (Pharmaceuticals) was acquired on 16-Jul-2007.

  • Who acquired Valentis (Pharmaceuticals)?

    Valentis (Pharmaceuticals) was acquired by Vaneltix Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process